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Abstract 
The study of inflammatory bowel disease, including Ulcerative Colitis and Crohn’s Disease, has relied largely upon the use of 
animal or cell culture models; neither of which can represent all aspects of the human pathophysiology. Presented herein is a 
dual flow microfluidic device which holds full thickness human intestinal tissue in a known orientation. The luminal and serosal 
sides are independently perfused ex vivo with nutrients with simultaneous waste removal for up to 72 hours. The microfluidic 
device maintains the viability and integrity of the tissue as demonstrated through Haematoxylin & Eosin staining, 
immunohistochemistry and release of lactate dehydrogenase. In addition, the inflammatory state remains in the tissue after 
perfusion on the device as determined by measuring calprotectin levels. It is anticipated that this human model will be extremely 
useful for studying the biology and testing novel interventions in diseased tissue. 
Introduction 
 
Despite intensive research into inflammatory bowel disease (IBD) i.e. Crohn’s Disease (CD) and Ulcerative Colitis (UC), the 
pathogenic mechanisms remain unclear.1-3 It is thought that a combination of environmental and genetic influences alter the 
bacterial composition of the intestines causing an uncontrolled immune response in the intestinal mucosa and leading to a 
breakdown of the epithelial barrier. This local reaction leads to an increased influx of intestinal material into the cell wall creating 
an inflammatory response within the gut.4-6 IBD is a chronic disease without medical cure and requires lifetime care with a 
possibility of surgery, as well as the increased risk of colorectal cancer.7-10  
Current research models into IBD either require inducing the disease in murine models or using cell culture both of which fail to 
fully replicate the extent of the disease seen in humans.11 Despite these drawbacks the models have helped to decipher 
underlying mechanisms of IBD pathogenesis as well as to evaluate a number of potential therapeutics. The most commonly used 
animal model is to induce a mouse into a “colitis like” state through the addition of a water soluble, negatively charged, sulphated 
polysaccharide known as dextran-sulphate sodium (DSS) into their diet.11,12 The mechanism by which DSS induces intestinal 
inflammation is unclear but it is likely the result of damage to the epithelial monolayer lining the large intestine which allows the 
dissemination of pro-inflammatory intestinal contents, e.g. bacteria and their products, into the underlying tissue.11,12 The colitis 
model induced by DSS remains very popular in IBD research due to its speed, simplicity and reproducibility.1,13  However this 
method of studying IBD does have some drawbacks, such as significant differences between both the mouse and human immune 
systems and the microbiota found in their respective intestines, as well as the associated costs with the upkeep and housing of 
animals. 
On the other hand cell culture models are commonly used which typically utilise a single cell type grown in a monolayer, whereas 
cells in vivo grow in 3D structures consisting of many different cell types arranged in a unique spatial arrangement interweaved 
with extracellular matrix.14,15 It is this interaction between neighbouring cells which guides developmental processes central for 
function; monolayer cell culture models cannot replicate this.16 Development of an in vitro, living, cell-based model of the 
intestine that mimics the mechanical, structural, absorptive, transport and pathophysiological properties of the gut along with 
its crucial microbial symbionts would accelerate pharmaceutical development and potentially reduce the numbers of animals 
used in research and drug testing.15,17  
An alternative method of studying intestinal tissue as a whole is the Ussing chamber which provides a valuable, time-proven, 
method for the measurement of electrolyte, nutrient and drug transport across epithelial tissues.18,19 The method was developed 
over 50 years ago by Hans Ussing as a means to understand the phenomenon of active NaCl transport, i.e. the capacity of cells to 
move ions or nutrients against an electrical and/or concentration gradient, which had previously been demonstrated by isotopic 
tracer experiments.18,19 Ussing chamber studies of intestinal mucosa have provided many of the key observations that moved our 
understanding of trans-epithelial transport processes toward a molecular basis. The Ussing chamber uses a 1-3 mm3 biopsy of 
human intestinal tissue immersed in a cell culture medium that is commonly kept alive between 6-8 hours.18,19 This allows for 
cell-cell interactions and tissue characteristics to be maintained, mimicking a more in vivo environment. However, this method 
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has some well-known drawbacks including: holding the tissue in place by pressure plates which crush the biopsy at the edges; 
the media containing the nutrients for the tissue is static and thus the waste products build up; in addition to the complexity and 
time required to establish each model. 
With the recognition that precise 3D structures are important for normal or pathophysiological function complex cell cultures are 
becoming more popular research tools, e.g. spheroids/organoids.20 An example of such research was highlighted by Marx et al 
who developed a four organ microfluidic device which used a 3D spheroid, equivalent to ten liver lobules, to mimic liver function 
along with 2D cell cultures to mimic kidney, skin and intestine behaviour in the model.21 However, such cell spheroid models are 
complicated, cumbersome and expensive when compared to the 2D culture methods. Another approach, pioneered by Ingber 
and colleagues, was to develop a thermally-bonded microfluidic device composed of two sides separated by a porous flexible 
membrane made of polydimethylsiloxane (PDMS) coated with extracellular matrix (ECM) and lined by human intestinal Caco-2 
epithelial cells to mimic the complex structure of a living intestine.15,17 The “gut on a chip” then had tubing attached to provide a 
source of media together with a vacuum chamber to mimic the constant muscular motions of the intestinal tissue. 15,17 
The advancement of using a microfluidic device means that it is now possible to maintain biopsies or slices of actual organs in a 
viable state e.g. artery on a chip.22 The approach is similar in nature to the Ussing chamber but overcomes many of the technical 
issues associated with this approach. Using a human biopsy removes the problem of not being sure whether the tissue is a true 
replica of the in vivo tissue, however the major concern of this approach is how to maintain viability. A number of studies have 
shown that full thickness biopsies of various human and animal tissues can be maintained in an in vitro device that mimics the in 
vivo environment in a relatively simple manner.23-26  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1: The dual flow device. Panel A: Schematic of the dual flow device used to hold human gut tissue in a known orientation. Panel B: Coloured 
food dye depicting the dual flow in the microfluidic device. 
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Developed herein is a dual flow microfluidic device, designed to mimic the transport of intestinal material inside of the gut 
(luminal surface) through one side of the device and mimic the blood supply on the “outside” of the tissue (serosal surface) 
providing the necessary nutrients to maintain the viability of the tissue for a number of days after removal from a patient. The 
dual flow device uses a similar approach as the Ussing chamber with improvements; as the tissue is not crushed to be held in 
place and it is not a static environment but undergoing continuous perfusion with fresh nutrients whilst simultaneously removing 
the waste products thereby better mimicking the in vivo environment. This device can be used to investigate pathophysiological 
mechanisms, microbe-tissue interaction and various treatments which have been known or suspected to aid in the treatment of 
IBD. 
Materials and Methods 
 
Full thickness intestinal sections were removed, following informed consent, from patients undergoing small bowel or large bowel 
resection (REC 13/YH/0173) and transported in media on ice to the laboratory. The dual flow device fabricated from glass (1.5 
cm x 1.5 cm) with a chamber milled using a CNC machine (1 cm x 0.5 cm x 200 µM) was created in-house (University of Hull, 
Chemistry Department). PDMS (Dow Corning, UK) was prepared at various thicknesses (dependent on thickness of the tissue 
biopsy) and cut to the size of the glass chip before been trimmed in alignment with the milled chamber of the glass chip with a 5 
mm punch biopsy needle (Harvard, UK). The tissue was cut with the same punch biopsy needle to ensure an exact fit, without 
sustained pressure as required in the Ussing chamber. The microfluidic components of tubing and connectors (Kinesis and Mengel 
Engineering respectively) allowed continuous perfusion of cell culture media {non-phenol red and phenol red Dulbecco modified 
Eagles media (DMEM) both supplemented with 10% v/v FBS, 1% v/v penicillin/streptomycin, 1.5% v/v 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES buffer) and 1% v/v minimal essential amino acids (MEM), (SLS, UK)} across the tissue to 
maintain viability. Double-sided adhesive was used to hold the glass to the PDMS, keeping the tissue in a known orientation (Fig 
1). The device was constructed in a sterile class II biological safety cabinet before being housed in a pre-heated incubator for the 
duration of the environment at 37°C, with a flow rate of 4 µL/min using a syringe pump (Harvard, UK). The effluent was collected 
over time and stored until analysis. All the components (except the tubing) were autoclaved before use. Household petroleum 
jelly (Vaseline™) was applied to the edges of the tissue to seal any gaps between the tissue and PDMS, ensuring that perfusion is 
only possible across the tissue. 
 
The Lactate Dehydrogenase (LDH) colourimetric assay (Roche) was used according to the standard protocol on aliquots of effluent 
(50 µL per sample analysed in triplicate in a 96 well plate). Tissue was lysed with a 10% v/v lysis solution from the kit at 68 hours 
to determine the level of viability that was maintained for the duration of the experiment. A calibration curve using known 
concentrations of LDH (measured in Units of activity) was created and values derived were finally divided by the wet weight of 
the tissue biopsy (mg) to allow comparison between samples. 
Tissue for sectioning was fixed in 4% w/v paraformaldehyde solution (Sigma Aldrich) for 24 hours before dehydration in alcohol 
and paraffin embedding (VWR). Tissue blocks were then sectioned at 10 µm and stained using Haematoxylin and Eosin Stain (H&E 
staining; Sigma Aldrich) before mounting with histomount (Sigma Aldrich). Sections of tissue were used for immunohistochemical 
staining of Ki-67 (MIB1, Dako) following standard microwave antigen retrieval to determine proliferating cells in the tissue.27 
Permeation studies of the intestinal mucosal layer were determined using two differently sized fluorescein isothiocyanate (FITC)-
dextran molecules: 2,000,000 and 50,000 molecular weight (Sigma Aldrich). Individually each dextran-FITC species was added to 
the culture media at 10% w/v and applied to the luminal surface of the tissue. After different lengths of time the tissue was snap 
frozen and sectioned using a cryostat (Leica CM 1950) before imaging by confocal microscopy. Controls were completed 
simultaneously using either a PDMS and petroleum jelly “plug” or petroleum jelly alone both of which acted as an impermeable 
barrier across the device. Previous work has already demonstrated that petroleum jelly is compatible with human tissue as 
commonly used to aid in wound healing.28 
Calprotectin, also known as s100a8, an inflammatory marker, was measured in the collected effluents using a duo set ELISA (RnD 
Systems Europe) following the manufacturer’s protocol. The minimal detectable level was 31.3 pg/ml. Concentrations were 
expressed per mg wet weight of the tissue biopsy. 
Results and Discussion 
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Once the sample had been taken from a patient undergoing a bowel resection it took a maximum of 1.5 h to establish the devices. 
This time involved transport and preparation using previously sterilised and prepared devices. If the devices were operated in the 
same facility as the surgical procedure it would be possible to establish devices in under 20 minutes, as the tissue processing is 
minimal and simple. 
Initial experiments were done to ensure the tissue could be held in place in the PDMS layer of the device correctly, and that 
transfer of media from one side to the other occurred through the tissue by perfusion not leaking around the edges. Phenol Red 
and non-phenol red media were perfused for 70 h as depicted in Fig 1 through the device and the effluents were sampled at 
multiple 2 h time points over 4 days; absorbance was measured at 450nm to detect the presence of phenol red (Fig 2).  Five 
independent tissue biopsies were tested in this way and demonstrated the continued separation of the media streams, ensuring 
the device does not leak. 
 
Fig 2: Two differently coloured media red and clear (phenol red and non phenol red) were continuously flowed (4 µL/min) over the tissue to 
maintain viability over the duration of the experiment (70 h), n=5, errors bars show standard deviation (S.D). The luminal surface was maintained 
via the phenol red media (red) and the stromal surface maintained with the non phenol red media (clear). 
The permeability of tissue is known to increase in IBD leading to an influx of bacteria into the lumen surface of the gastrointestinal 
tract which causes the inflammatory immune response. 4-6 When either FITC-dextran species was added to the luminal media 
they passed through the tissue within 25 minutes (Fig 3). Biopsies from five independent patients were studied and no obvious 
differences were observed in perfusion kinetics. Similarly, when devices were set up with only petroleum jelly filling the chamber 
as in Fig 2, no perfusion of the fluorescent dextran was observed over the 68 h period (data not shown) supporting the fact that 
perfusion only occurs through the tissue. The relatively rapid nature of the perfusion is in contrast to some other models of 
intestinal mucosa, e.g. a porcine model developed by Westerhout et al.29 who reported <0.5% leakage of FITC-dextran of 4000 
molecular weight over a 3 h time frame. One potential explanation for this difference is that the previous work was not a disease 
model and, as has been stated above, IBD is well known to cause an increase in mucosa permeability. 
Further characterisation of the device shows tissue is maintained at viable levels by measuring cell death via LDH which is released 
from dead and dying cells throughout the length of experiment. To show that viable tissue was present at the end of the 
maintenance period (68 h) tissue was lysed by the addition of buffer containing detergent (Fig 4). In addition to the spike of LDH 
release following introduction of a detergent-containing solution a relatively high release of LDH is seen within the first 24 h of 
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the tissue being placed in the microfluidic device; this pattern of release has been observed previously when studying other 
tissues such as rat liver, human tumours (ovarian and head and neck carcinomas) in similar microfluidic devices.  The initial high 
levels of LDH release are thought to be due to unavoidable damage caused by the handling of the tissue from the resection and 
then preparation for insertion into the device.23-26,30,31 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig  3: FITC-Dextran was flowed through the device on the luminal surface only from time zero to ensure the device does not leak around the tissue 
to ensure passage is only through the tissue. Panel A: shows the FITC flowed through on the Luminal surface remains on the luminal side of the 
device and is not measurable on the serosal side of the tissue in the experiments time scale (36 h). Panel B: a frozen section of tissue used to show 
fluorescence in the tissue from the FITC dextran, depicting permeability of the tissue. Panel C: negative control to show the tissue does not auto 
fluoresce.  
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Fig  4: LDH Assay of collected effluent, lysis buffer added at 68 hours to purposely kill tissue and ensure viability remains in tissue during the time 
in the microfluidic device, (n=5).  
To quantify the proportion of viable cells that remained in the tissue throughout the duration of the experiment a portion of the 
tissue taken from patients was immediately put into 10% v/v lysis solution for 24 h and the total LDH release was measured. 
Similarly, tissue which had been in the device for 24 or 72 h was also treated in this way and the total amounts released were 
quantified (Fig 5). The LDH release given after 24 and 72 h was expressed as a percentage of the initial concentration. These 
experiments show that almost 80% of the tissue remains viable having been maintained in the dual flow device for 3 days. 
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Fig 5: Total LDH release comparing fresh tissue (blue) taken from patient, 24 h (red) in dual device and 72 h (green) in dual flow device (n=5). 
 
Viability was further evaluated by studying the architecture of the tissue, before and after being maintained in the device using 
H&E staining. A Consultant Histopathologist (LK) reviewed the stained sections taken immediately from the resection specimen 
(fresh) and after 72 h of on-chip maintenance. The crypts and goblet cells in the lumen of the tissue were found intact in both 
small and large bowel and overall relatively little changes were seen; it was still possible to histologically report the tumour using 
the biopsy recovered from the device (fig 6). In addition to demonstrating retention of architecture for the duration of the time 
spent in the device, cell proliferation via Ki-67 staining was also studied with the proliferating cells possessing a brown-staining 
nuclei. This analysis again showed that the structures of the large bowel remained identifiable and also that proliferating cells 
were found in the tissue after 72 h of perfusion on the device (fig 7). 
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Fig 6: H&E staining of IBD small and large bowel tissue stained prior to (A1 and A2) and after maintenance for 72 h (B1, B2 and C1, C2) 
in the dual flow device. All tissue was fixed and sectioned (5 µm), (representative of 10 independent patient samples). 
A1: IBD large bowel tissue (fresh; immediately fixed) x20 
A2: IBD large bowel tissue (fresh; immediately fixed) x40 
B1: IBD small bowel tissue x20 magnification (on-chip) 
B2: IBD small bowel tissue x40 (on-chip) 
C1: IBD large bowel tissue x40 (on-chip) 
C2: IBD large bowel tissue x100 (on-chip) 
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Fig 7: Ki-67 Staining of tissue before been in the device (Panel A) x20 and after being in the device for 72 h(Panel B) x 100 (representative 
of 4 independent samples) to show the remains identifiable and also proliferation (shown by staining as brown spots) is still  present in 
the tissue after been in the device for 72 h. 
 
IBD is characterised by chronic inflammation and therefore having shown that biopsies remained viable in the device an analysis 
of the effluent was undertaken for the determination of the concentration of Calprotectin (s100a8). This factor is commonly used 
as a marker for inflammation in serum or plasma. Increased levels of calprotectin were seen in all the IBD samples over a 70 h 
period when compared with the control samples, i.e. healthy bowel tissue (fig 8). Interestingly no difference in levels was 
observed over time, and the levels were similar in both the luminal and stromal effluents. 
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A common question with any new model is its robustness and reliability. The dual-flow device described herein can be set-up 
within 20 minutes and has a 79% success rate (36/46 devices with samples from 22 patients) of generating data, which could be 
used clinically e.g. the s100a8 data, LDH release for maintenance of the tissue and the staining methods all aid in diagnosis of 
disease. Current methods which use human or animal intestinal tissue rely on methods which do not fully incorporate the complex 
system of the gut e.g. lumen-microbe interaction.32 The Ussing chamber’s main limitation is that it can only maintain tissue 
outside of the human body for a few hours.29 However the use of microfluidics in maintaining tumour tissue has shown that such 
perfused systems can potentially extend this time frame with >7 days being routine in some devices.24-26,33,34 
 
As the causes of IBD remain largely unknown many patients with the disease may develop complications which are potentially 
life-threatening including an increased risk of colorectal cancer.10 There is a significant morbidity and mortality in active young 
people requiring elective or emergency surgery for IBD, which has a significant impact on the quality of life of sufferers. However, 
in some cases the disease can be effectively managed especially if enhanced prognostic tools are available. Additionally, 
treatment for IBD is life-long as there is currently no cure, at a cost to the NHS of about £720 million per annum; an average cost 
of £3,000 per year per patient.35,36 It is hoped that this new microfluidic platform will allow future treatments to be more quickly 
tested and translated to patients. The work presented here is focused on mimicking the human system in microfluidic devices to 
better understand disease and the various ways we can deliver targeted drug therapies. It is probable that development of novel 
organ- or human-on-a-chip,37-39 such as that described here will open up new ways of testing the downstream effects seen for 
example in the kidneys or liver.40  
Conclusions 
In conclusion we have developed a device which can maintain intestinal tissue according to LDH release, H&E and Ki-67 staining 
for up to 72 h, after removal from a patient undergoing a bowel resection, in a functional and “normal” anatomical state. This 
novel device provides a human-based model for the in vitro study of IBD and the investigation of therapeutic interventions 
providing a better understanding of the disease which current methods of cell culture and animal work fail to replicate fully. 
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